viewIQ-AI Limited

IQ-AI’s Imaging Biometrics featured in American Journal of Neuro Radiology

The investment firm said the publication highlighted a study involving magnetic resonance dynamic susceptibility contrast in magnetic resonance imaging (DSC-MRI) for brain tumour patients

Medical paper stack
AJNR is a peer-reviewed medical journal

IQ-AI Limited’s (LON:IQAI) subsidiary Imaging Biometrics (IB) has been featured in a publication from the peer-reviewed American Journal of Neuro Radiology (AJNR).

The investment firm said the publication, titled "Moving Towards a Consensus DSC-MRI Protocol: Validation of A Low Flip Angle Single Dose Option as a Reference Standard for Brain Tumors", highlighted a study involving magnetic resonance dynamic susceptibility contrast in magnetic resonance imaging (DSC-MRI) for brain tumour patients.

READ: IQ-AI surges after raising £268,500 in loan notes issue

IB's software products, IB Neuro and IB Delta Suite, were used to generate quantitative perfusion relative cerebral blood volume (rCBV) values with the specific goal of determining if a single-dose of contrast agent, combined with a low-flip angle DSC-MRI method, can provide rCBV information comparable to the commonly accepted double-dose method.

DSC-MRI is the most common approach used to measure brain tumour perfusion. It provides critical information regarding tumour grade, treatment response, and prognosis. Despite these benefits, full adoption has been impeded due to disagreement regarding how to collect and analyse the data.

The multi-centre team, including researchers from the Medical College of Wisconsin, The Mayo Clinic, The Barrow Neurological Institute, and Rhode Island Hospital, revealed an interesting performance-based option for 3T MRI scanners.

While using the well-established preload of contrast agent and applying the proven contrast leakage correction methods of IB Neuro, the team realized that data obtained without a preload dose of contrast and a lower flip-angle produced rCBV maps comparable to the accepted double-dose option.

Moreover, an even better and less variable agreement was obtained between the double-dose and no-preload method when the rCBV data was standardised using IB Neuro's exclusive technology. Standardisation is an automated image intensity calibration step that renders the data to be truly quantitative - independent of scanner, field strength, patient or time point.

Michael Schmainda, president of Imaging Biometrics: "This is the first study that directly compares the single-dose (no preload), low flip angle method to the conventional double-dose method for creation of rCBV maps. This study is a significant step towards creating the standard in DSC MRI for brain tumor patients, and it has the added benefit of reducing the amount of contrast agent required to obtain good quality output. This marks an important step towards our ultimate goal of providing a contrast free option for MR imaging."

In mid-morning trading Tuesday, IQ-AI shares were down 8.9% at 1p.

Quick facts: IQ-AI Limited

Price: 3 GBX

Market: LSE
Market Cap: £4.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...



Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant. Under the agreement with US firm AI...

on 15/1/20

2 min read